ARMISTICE CAPITAL, LLC - Q4 2018 holdings

$1.32 Billion is the total value of ARMISTICE CAPITAL, LLC's 71 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 81.6% .

 Value Shares↓ Weighting
AMAG SellAMAG PHARMACEUTICALS INC$28,527,000
-31.4%
1,878,000
-9.7%
2.16%
-13.4%
REGN SellREGENERON PHARMACEUTICALS$26,145,000
-13.7%
70,000
-6.7%
1.98%
+9.0%
PGNX SellPROGENICS PHARMACEUTICALS IN$23,940,000
-38.0%
5,700,000
-7.4%
1.81%
-21.7%
SJM SellSMUCKER J M CO$22,438,000
-57.6%
240,000
-53.5%
1.70%
-46.5%
CLLS SellCELLECTIS S Asponsored ads$9,807,000
-42.1%
589,000
-1.8%
0.74%
-26.9%
CPRX SellCATALYST PHARMACEUTICALS INC$2,650,000
-58.1%
1,380,000
-17.5%
0.20%
-47.0%
ORMP SellORAMED PHARM INC$1,629,000
-46.4%
542,944
-13.0%
0.12%
-32.4%
ONTX SellONCONOVA THERAPEUTICS INC$62,000
-92.4%
29,216
-73.7%
0.01%
-89.8%
RTTR SellRITTER PHARMACEUTICALS INC$30,000
-91.2%
50,771
-72.1%
0.00%
-90.0%
TTNP ExitTITAN PHARMACEUTICALS INC DE$0-220,000
-100.0%
-0.00%
VXRT ExitVAXART INC$0-150,000
-100.0%
-0.03%
PTIE ExitPAIN THERAPEUTICS INC$0-2,164,000
-100.0%
-0.13%
IPCIF ExitINTELLIPHARMACEUTICS INTL IN$0-860,000
-100.0%
-0.14%
T ExitAT&T INC$0-100,000
-100.0%
-0.20%
JCPNQ ExitPENNEY J C INCcall$0-2,300,000
-100.0%
-0.23%
PDLI ExitPDL BIOPHARMA INC$0-1,800,000
-100.0%
-0.28%
CMRX ExitCHIMERIX INC$0-1,300,000
-100.0%
-0.30%
APRN ExitBLUE APRON HLDGS INCcall$0-3,000,000
-100.0%
-0.31%
MED ExitMEDIFAST INC$0-24,000
-100.0%
-0.32%
FTCH ExitFARFETCH LTDord sh cl a$0-200,000
-100.0%
-0.33%
NVLNF ExitNOVELION THERAPEUTICS INC$0-1,856,000
-100.0%
-0.33%
TLRDQ ExitTAILORED BRANDS INC$0-300,000
-100.0%
-0.45%
LULU ExitLULULEMON ATHLETICA INC$0-50,000
-100.0%
-0.49%
FB ExitFACEBOOK INCcl a$0-50,000
-100.0%
-0.49%
FND ExitFLOOR & DECOR HLDGS INCcl a$0-300,000
-100.0%
-0.54%
BDSI ExitBIODELIVERY SCIENCES INTL IN$0-3,292,000
-100.0%
-0.55%
EAT ExitBRINKER INTL INC$0-200,000
-100.0%
-0.56%
RDUS ExitRADIUS HEALTH INC$0-658,000
-100.0%
-0.70%
ONCE ExitSPARK THERAPEUTICS INC$0-228,000
-100.0%
-0.75%
BLUE ExitBLUEBIRD BIO INC$0-88,000
-100.0%
-0.77%
GPS ExitGAP INC DEL$0-524,000
-100.0%
-0.91%
BBY ExitBEST BUY INC$0-200,000
-100.0%
-0.95%
MDGL ExitMADRIGAL PHARMACEUTICALS INC$0-80,000
-100.0%
-1.03%
PETS ExitPETMED EXPRESS INC$0-532,000
-100.0%
-1.05%
QRTEA ExitQURATE RETAIL INC$0-900,000
-100.0%
-1.20%
VNDA ExitVANDA PHARMACEUTICALS INC$0-900,000
-100.0%
-1.24%
SGMS ExitSCIENTIFIC GAMES CORP$0-900,000
-100.0%
-1.37%
DESP ExitDESPEGAR COM CORP$0-1,564,000
-100.0%
-1.58%
HAIN ExitHAIN CELESTIAL GROUP INC$0-1,000,000
-100.0%
-1.63%
RL ExitRALPH LAUREN CORPcl a$0-218,000
-100.0%
-1.80%
CAR ExitAVIS BUDGET GROUP$0-1,000,000
-100.0%
-1.93%
KORS ExitMICHAEL KORS HLDGS LTD$0-536,000
-100.0%
-2.21%
HBI ExitHANESBRANDS INC$0-2,000,000
-100.0%
-2.21%
HOG ExitHARLEY DAVIDSON INC$0-824,000
-100.0%
-2.24%
UTHR ExitUNITED THERAPEUTICS CORP DEL$0-292,000
-100.0%
-2.24%
INCY ExitINCYTE CORPcall$0-700,000
-100.0%
-2.90%
HAIN ExitHAIN CELESTIAL GROUP INCcall$0-2,000,000
-100.0%
-3.26%
CAKE ExitCHEESECAKE FACTORY INCcall$0-1,100,000
-100.0%
-3.54%
CPB ExitCAMPBELL SOUP COcall$0-2,000,000
-100.0%
-4.40%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ENANTA PHARMACEUTICALS INC30Q3 20232.7%
SPDR S&P 500 ETF TR28Q3 202329.5%
MADRIGAL PHARMACEUTICALS INC27Q3 20232.9%
VANDA PHARMACEUTICALS INC26Q3 20219.4%
REGENERON PHARMACEUTICALS25Q3 20233.2%
ENERGIZER HLDGS INC NEW22Q2 20233.7%
ANTARES PHARMA INC21Q3 20206.6%
INCYTE CORP21Q3 20232.8%
VOYAGER THERAPEUTICS INC21Q3 20232.0%
BLUEBIRD BIO INC20Q4 20211.8%

View ARMISTICE CAPITAL, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ARMISTICE CAPITAL, LLC Q4 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Avalo Therapeutics, Inc.June 28, 2023588,8504.7%
Addex Therapeutics Ltd.February 16, 2023675,2955.0%
Arcadia Biosciences, Inc.February 14, 20232,675,40910.0%
Avinger IncFebruary 14, 2023789,40010.0%
Baudax Bio, Inc.February 14, 20231,165,7095.0%
BIORA THERAPEUTICS, INC.February 14, 202312,989,6485.7%
Bit Digital, IncFebruary 14, 20233,161,8893.7%
Bruush Oral Care Inc.February 14, 20231,122,92210.0%
CATALYST PHARMACEUTICALS, INC.Sold outFebruary 14, 202300.0%
Clarus Therapeutics Holdings, Inc.February 14, 20232,732,1695.0%

View ARMISTICE CAPITAL, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View ARMISTICE CAPITAL, LLC's complete filings history.

Compare quarters

Export ARMISTICE CAPITAL, LLC's holdings